



Patient Report

Specimen ID: 350-988-9522-0
Control ID:

Acct #: 90000999 Phone: (336) 436-8645 Rte: 00

LabCorp Test Master

Test Account

5450 Millstream Road

MCLEANSVILLE NC 27301



SAMPLE REPORT, 550140

Patient Details

DOB: 01/01/1960
Age(y/m/d): 059/11/15
Gender: M SSN:
Patient ID:

Specimen Details

Date collected: 12/16/2019 0000 Local
Date received: 12/16/2019
Date entered: 12/16/2019
Date reported: 12/17/2019 0000 ET

Physician Details

Ordering:
Referring:
ID:
NPI:

General Comments & Additional Information

Clinical Info: **NORMAL REPORT**

Ordered Items

NASH FibroSure

TESTS	RESULT	FLAG	UNITS	REFERENCE	INTERVAL	LAB
NASH FibroSure						
NASH FibroSURE Results:						01
Fibrosis Score	0.40	High		0.00 - 0.21		01
Fibrosis Stage	F1-F2					01
.						01
Steatosis Score	0.31	High		0.00 - 0.30		01
Steatosis Grade						01
S0 - S1	No Steatosis - Minimal Steatosis					01
.						01
NASH Score	0.25			0.25		01
NASH Grade						01
NO - Not NASH						01
.						01
Analysis:						01
Height:	76		in			01
Weight:	160		LBS			01
Alpha 2-Macroglobulins, Qn	150		mg/dL	110 - 276		01
Haptoglobin	45		mg/dL	29 - 370		01
Apolipoprotein A-1	125		mg/dL	101 - 178		01
Bilirubin, Total	0.5		mg/dL	0.0 - 1.2		01
GGT	55		IU/L	0 - 65		01
ALT (SGPT) P5P	44		IU/L	0 - 55		01
AST (SGOT) P5P	35		IU/L	0 - 40		01
Cholesterol, Total	100		mg/dL	100 - 199		01
Glucose, Serum	75		mg/dL	65 - 99		01
Triglycerides	120		mg/dL	0 - 149		01
.						01
Interpretations:						01

Quantitative results of 10 biochemicals in combination with age, gender, height, and weight, are analyzed using a computational algorithm to provide a quantitative surrogate marker (0.0-1.0) of liver fibrosis (Metavir F0-F4), hepatic

Patient: **SAMPLE REPORT, 550140**
 DOB: 01/01/1960

Patient ID:

Control ID:

Specimen ID: 350-988-9522-0
 Date collected: 12/16/2019 0000 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
-------	--------	------	-------	--------------------	-----

steatosis (0.0-1.0, S0-S3), and Non-Alcoholic Steato-Hepatitis (NASH) (0.0-0.75, N0-N2). The absence of steatosis (S<0.38) precludes the diagnosis of NASH.

Fibrosis marker: In a study of 171 Non-Alcoholic Fatty Liver Disease (NAFLD) patients where 23% had significant NAFLD fibrosis (Metavir F2-F4) and 11% had cirrhosis by liver biopsy, a fibrosis result of >0.3 yielded a sensitivity of 83% and a specificity of 78% for the detection of significant fibrosis(1).

Steatosis Marker: In a population of 744 patients (583 HCV, 18 HBV, 69 NAFLD, and 74 alcoholic disease patients), where 36% had significant steatosis (>5%) on a liver biopsy, a steatosis score >0.5 had a sensitivity of 71% and a specificity of 72% for identification of significant steatosis(2).

NASH marker: In a population of 257 NAFLD patients, where 62% had at least some NASH by liver biopsy, a prediction of NASH had a sensitivity of 88% for identifying NASH and a specificity of 50%(3).

Fibrosis Scoring:

<0.21 = Stage F0 - No fibrosis
 0.21 - 0.27 = Stage F0 - F1
 0.27 - 0.31 = Stage F1 - Portal fibrosis
 0.31 - 0.48 = Stage F1 - F2
 0.48 - 0.58 = Stage F2 - Bridging fibrosis with few septa
 0.58 - 0.72 = Stage F3 - Bridging fibrosis with many septa
 0.72 - 0.74 = Stage F3 - F4
 >0.74 = Stage F4 - Cirrhosis

Steatosis Grading

< 0.30 = S0 - No Steatosis
 0.30 to 0.38 = S0 - S1
 0.38 to 0.48 = S1 - Minimal Steatosis
 0.48 to 0.57 = S1 - S2
 0.57 to 0.67 = S2 - Moderate Steatosis
 0.67 to 0.69 = S2 - S3
 > 0.69 = S3 - Marked or Severe Steatosis

NASH Scoring

0.25 = N0 - Not NASH
 0.50 = N1 - Borderline or probable NASH
 0.75 = N2 - NASH

Limitations:

NASH FibroSure is recommended for patients with suspected non-alcoholic fatty liver disease. It is not recommended for patients with other liver diseases. It is also not recommended in patients with Gilbert Disease, acute hemolysis, acute viral hepatitis, drug induced hepatitis, genetic liver disease, autoimmune hepatitis and/or extra-hepatic cholestasis. Any of these clinical situations may lead to inaccurate quantitative predictions of fibrosis.

Comment:

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration. The FDA has determined that such clearance or

Patient: **SAMPLE REPORT, 550140**
 DOB: 01/01/1960

Patient ID:

Control ID:

Specimen ID: 350-988-9522-0
 Date collected: 12/16/2019 0000 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE	INTERVAL	LAB
-------	--------	------	-------	-----------	----------	-----

approval is not necessary.

For questions regarding this report please contact
 customer service at 1-800-788-9223.

References:

1. Ratziu V. et al. Diagnostic Value of Biochemical Markers (FibroTest) for the prediction of Liver Fibrosis in patients with Non-Alcoholic Fatty Liver Disease. BMC Gastroenterology 2006; 6:6.
2. Poynard, T. et al. The Diagnostic Value of Biomarkers (Steato Test) for the Prediction of Liver Steatosis. Comparative Hepatol. 2005; 4:10.
3. Poynard, T, Ratziu, Charlotte F, et al. Diagnostic value of biochemical markers (NASH TEST) for the prediction of non alcohol steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterology 2006; 6:34 doi:10.1186/1471-230X-6-34.

01	BN	LabCorp Burlington 1447 York Court, Burlington, NC 27215-3361	Dir: Sanjai Nagendra, MD
----	----	--	--------------------------

For inquiries, the physician may contact **Branch: 800-222-7566 Lab: 336-436-2762**



Patient Report

Specimen ID: 350-988-9523-0
Control ID:

Acct #: 90000999 Phone: (336) 436-8645 Rte: 00

LabCorp Test Master

Test Account

5450 Millstream Road

MCLEANSVILLE NC 27301



SAMPLE REPORT, 550140

Patient Details

DOB: 01/01/1980

Age(y/m/d): 039/11/15

Gender: M SSN:

Patient ID:

Specimen Details

Date collected: 12/16/2019 0000 Local

Date received: 12/16/2019

Date entered: 12/16/2019

Date reported: 12/17/2019 0000 ET

Physician Details

Ordering:

Referring:

ID:

NPI:

General Comments & Additional Information

Clinical Info: **ABNORMAL REPORT**

Ordered Items

NASH FibroSure

TESTS	RESULT	FLAG	UNITS	REFERENCE	INTERVAL	LAB
NASH FibroSure						
NASH FibroSURE Results:						
Fibrosis Score	0.32	High		0.00 - 0.21		01
Fibrosis Stage	F1-F2					01
.						01
Steatosis Score	0.41	High		0.00 - 0.30		01
Steatosis Grade	S1 - Mild Steatosis					01
.						01
NASH Score	0.50	High		0.25		01
NASH Grade	N1 - Borderline or probable NASH					01
.						01
Analysis:						
Height:	71		in			01
Weight:	180		LBS			01
Alpha 2-Macroglobulins, Qn	277	High	mg/dL	110 - 276		01
Haptoglobin	318	High	mg/dL	17 - 317		01
Apolipoprotein A-1	179	High	mg/dL	101 - 178		01
Bilirubin, Total	1.3	High	mg/dL	0.0 - 1.2		01
GGT	67	High	IU/L	0 - 65		01
ALT (SGPT) P5P	56	High	IU/L	0 - 55		01
AST (SGOT) P5P	55	High	IU/L	0 - 40		01
Cholesterol, Total	225	High	mg/dL	100 - 199		01
Glucose, Serum	130	High	mg/dL	65 - 99		01
Triglycerides	155	High	mg/dL	0 - 149		01
.						01
Interpretations:						

Quantitative results of 10 biochemicals in combination with age, gender, height, and weight, are analyzed using a computational algorithm to provide a quantitative surrogate marker (0.0-1.0) of liver fibrosis (Metavir F0-F4), hepatic

Patient: **SAMPLE REPORT, 550140**
 DOB: 01/01/1980

Patient ID:

Control ID:

Specimen ID: 350-988-9523-0
 Date collected: 12/16/2019 0000 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
-------	--------	------	-------	--------------------	-----

steatosis (0.0-1.0, S0-S3), and Non-Alcoholic Steato-Hepatitis (NASH) (0.0-0.75, N0-N2). The absence of steatosis (S<0.38) precludes the diagnosis of NASH.

Fibrosis marker: In a study of 171 Non-Alcoholic Fatty Liver Disease (NAFLD) patients where 23% had significant NAFLD fibrosis (Metavir F2-F4) and 11% had cirrhosis by liver biopsy, a fibrosis result of >0.3 yielded a sensitivity of 83% and a specificity of 78% for the detection of significant fibrosis(1).

Steatosis Marker: In a population of 744 patients (583 HCV, 18 HBV, 69 NAFLD, and 74 alcoholic disease patients), where 36% had significant steatosis (>5%) on a liver biopsy, a steatosis score >0.5 had a sensitivity of 71% and a specificity of 72% for identification of significant steatosis(2).

NASH marker: In a population of 257 NAFLD patients, where 62% had at least some NASH by liver biopsy, a prediction of NASH had a sensitivity of 88% for identifying NASH and a specificity of 50%(3).

Fibrosis Scoring:

<0.21 = Stage F0 - No fibrosis
 0.21 - 0.27 = Stage F0 - F1
 0.27 - 0.31 = Stage F1 - Portal fibrosis
 0.31 - 0.48 = Stage F1 - F2
 0.48 - 0.58 = Stage F2 - Bridging fibrosis with few septa
 0.58 - 0.72 = Stage F3 - Bridging fibrosis with many septa
 0.72 - 0.74 = Stage F3 - F4
 >0.74 = Stage F4 - Cirrhosis

Steatosis Grading

< 0.30 = S0 - No Steatosis
 0.30 to 0.38 = S0 - S1
 0.38 to 0.48 = S1 - Minimal Steatosis
 0.48 to 0.57 = S1 - S2
 0.57 to 0.67 = S2 - Moderate Steatosis
 0.67 to 0.69 = S2 - S3
 > 0.69 = S3 - Marked or Severe Steatosis

NASH Scoring

0.25 = N0 - Not NASH
 0.50 = N1 - Borderline or probable NASH
 0.75 = N2 - NASH

Limitations:

NASH FibroSure is recommended for patients with suspected non-alcoholic fatty liver disease. It is not recommended for patients with other liver diseases. It is also not recommended in patients with Gilbert Disease, acute hemolysis, acute viral hepatitis, drug induced hepatitis, genetic liver disease, autoimmune hepatitis and/or extra-hepatic cholestasis. Any of these clinical situations may lead to inaccurate quantitative predictions of fibrosis.

Comment:

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration. The FDA has determined that such clearance or

Patient: SAMPLE REPORT, 550140
DOB: 01/01/1980
Patient ID:
Control ID:
Specimen ID: 350-988-9523-0
Date collected: 12/16/2019 0000 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE	INTERVAL	LAB
-------	--------	------	-------	-----------	----------	-----

approval is not necessary.

For questions regarding this report please contact customer service at 1-800-788-9223.

References:

1. Ratziu V. et al. Diagnostic Value of Biochemical Markers (FibroTest) for the prediction of Liver Fibrosis in patients with Non-Alcoholic Fatty Liver Disease. BMC Gastroenterology 2006; 6:6.
2. Poynard, T. et al. The Diagnostic Value of Biomarkers (Steato Test) for the Prediction of Liver Steatosis. Comparative Hepatol. 2005; 4:10.
3. Poynard, T, Ratziu, Charlotte F, et al. Diagnostic value of biochemical markers (NASH TEST) for the prediction of non alcohol steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterology 2006; 6:34 doi:10.1186/1471-230X-6-34.

01	BN	LabCorp Burlington 1447 York Court, Burlington, NC 27215-3361	Dir: Sanjai Nagendra, MD
----	----	--	--------------------------

For inquiries, the physician may contact **Branch: 800-222-7566 Lab: 336-436-2762**